AKT1 and colorectal carcinoma: PI3K mutations were more frequent in the early stages of CRC progression (stages I and II) when comparing patients with no mutations and those with PI3K mutations alone (56.4% vs. 32.1%), suggesting that genetic variants in the AKT/PI3K pathway genes may be associated with early clinicopathological features in CRC patients.